Dr. Girish Nallur is the Founder & CEO of Vistara Bioscience, a biotech company based in Guilford, Connecticut, focused on developing proteomics-driven tools for targeted protein degradation (TPD). With over 20 years of experience in molecular biology, drug discovery, and technology development, Dr. Nallur leads efforts to advance Vistara’s proprietary platforms such as PINTAC, which enable detailed mapping of protein degradation pathways and support the design of safer, more effective therapeutics for cancer, inflammation, and neurodegenerative diseases. He holds a Ph.D. in Molecular Biology and has held research and leadership roles at institutions including Yale, Scripps, and the Wistar Institute.

Dr. Paul Seidler is an Assistant Professor at USC’s Alfred E. Mann School of Pharmacy, specializing in drug discovery for neurodegenerative diseases like Alzheimer’s. His research focuses on targeting toxic tau protein aggregates using advanced structural biology techniques such as cryo-EM and X-ray crystallography. He also explores the blood–brain barrier to improve drug delivery. His work is widely published and supported by organizations like BrightFocus and the Alzheimer’s Drug Discovery Foundation.

Dr. Thomas Caulfield is the Founder & CEO of Digital Ether Computing, an AI-driven biotech company based in Miami, Florida, focused on precision drug discovery and functional genomics. With over 30 years of experience spanning physics, materials science, biochemistry, and medicinal chemistry, he previously led drug discovery efforts at Mayo Clinic's Center for Individualized Medicine. At Digital Ether, Dr. Caulfield integrates advanced computational tools—including molecular dynamics, generative AI, and structural modeling—to design novel therapeutics such as small molecules, peptides, PROTACs, and RNA-based drugs for complex diseases like cancer and neurodegeneration.